EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Mitigating Post-operative Right Ventricular Dysfunction After Left Ventricular Assist Device: The RV Protection Study

Anthony J Kanelidis, Leo Gozdecki, Mark N Belkin, Sara Kalantari, Ann Nguyen, Ben B Chung, Stanley Swat, Nitasha Sarswat, Gene Kim, Krystina Chickerillo, Justin Okray, Annalyse Hubbell und 9 weitere

Journal of Cardiac Failure · 2026

DOI: 10.1016/j.cardfail.2025.01.017 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Cardiac Failure, 2026. Verfasst von Anthony J Kanelidis und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Section of Cardiology, Advanced Heart Failure and Transplant Cardiology, University of Chicago Medical Center, Chicago, IL. Hauptthemen laut MEDLINE: Heart-Assist Devices, Ventricular Dysfunction, Right, Postoperative Complications, Heart Failure. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Despite improvements in hemocompatibility-related adverse events (HRAEs) with the HeartMate 3 left ventricular assist device (LVAD), hemodynamic-related events (HDREs), such as right ventricular failure (RVF) and aortic insufficiency, still result in considerable morbidity and mortality. We investigated a comprehensive, upfront RV protection strategy combining hemodynamic, ventilatory and pharmaceutical optimization to mitigate the risk of RVF. METHODS/RESULTS: Participants were prospectively randomized in a 1:1 fashion to either the RV-protection strategy or usual care for post-operative LVAD management. The RV-protection strategy targeted RV afterload (inhaled NO ≥ 48 hrs, PCWP 8), RV contractility (IV inotropes), rate/rhythm control (HR >100, normal sinus), ventilatory management (SpO2 >95, PaCO2 < 50, plateau pressure < 30, PEEP ≤ 5), and RV geometry (echo-guided septal position). The primary outcome was survival free from any HDREs or HRAEs at 24 weeks. Secondary outcomes included severe RVF, according to INTERMACS and ARC definitions. Twenty participants were randomized: 10 to the RV-protection strategy and 10 to usual care. The median age was 60 years (IQR 54-69), 50% were Black, and 50% had ischemia. At 24 weeks, the RV-protection strategy showed significantly greater survival rates free from HDREs or HRAEs compared to usual care (80% vs 40%; P = 0.04). Event-free survival for HRAEs resulted in similar findings. No HDREs occurred with the RV protection strategy vs 3 (30%) with usual care (P = 0.067). Similarly, severe RVF according to INTERMACS or ARC did not occur in the RV protection strategy vs 3 (30%) in the usual-care cohort (P = 0.20). CONCLUSIONS: Participants receiving a novel, comprehensive, upfront RV protection strategy post-LVAD implantation had significantly greater survival rates free from HDREs or HRAEs at 24 weeks.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart-Assist DevicesVentricular Dysfunction, RightPostoperative ComplicationsHeart FailureHumansMaleMiddle AgedFemaleProspective StudiesAgedFollow-Up Studies

Stichwörter der Autor:innen

Left ventricular assist devicehemocompatibility-related adverse eventshemodynamic-related eventsright ventricular failure

Autor:innen und Institutionen

  • Department of Medicine, Section of Cardiology, Advanced Heart Failure and Transplant Cardiology, University of Chicago Medical Center, Chicago, IL.
  • Department of Surgery, Section of Cardiac Surgery, University of Chicago Medical Center, Chicago, IL.
  • Department of Anesthesia and Critical Care, University of Chicago Medical Center, Chicago, IL.
  • Department of Medicine, Section of Cardiology, Advanced Heart Failure and Transplant Cardiology, Ohio State University, Columbus, OH.
  • Centre for Quantitative Medicine, Duke-NUS Medical School, National University of Singapore, Singapore, Singapore.
  • Department of Medicine, Section of Cardiology, Advanced Heart Failure and Transplant Cardiology, University of Chicago Medical Center, Chicago, IL. Electronic address: jgrinstein@bsd.uchicago.edu.

Zitieren

APA

Kanelidis, A. J., Gozdecki, L., Belkin, M. N., Kalantari, S., Nguyen, A., Chung, B. B., Swat, S., Sarswat, N., Kim, G., Chickerillo, K., Okray, J., Hubbell, A., Creighton, S. K., Jung, C. Y., Bole, I., Saffari, S. E., O'Connor, M., Ota, T., Jeevanandam, V., …, & Grinstein, J. (2026). Mitigating Post-operative Right Ventricular Dysfunction After Left Ventricular Assist Device: The RV Protection Study. Journal of Cardiac Failure. https://doi.org/10.1016/j.cardfail.2025.01.017

Vancouver

Kanelidis AJ, Gozdecki L, Belkin MN, Kalantari S, Nguyen A, Chung BB, et al. Mitigating Post-operative Right Ventricular Dysfunction After Left Ventricular Assist Device: The RV Protection Study. Journal of Cardiac Failure. 2026. doi:10.1016/j.cardfail.2025.01.017

BibTeX
@article{Kanelidis2026,
  author = {Kanelidis, Anthony J and Gozdecki, Leo and Belkin, Mark N and Kalantari, Sara and Nguyen, Ann and Chung, Ben B and Swat, Stanley and Sarswat, Nitasha and Kim, Gene and Chickerillo, Krystina and Okray, Justin and Hubbell, Annalyse and Creighton, Shana K and Jung, Christine Y and Bole, Indra and Saffari, Seyed Ehsan and O'Connor, Michael and Ota, Takeyoshi and Jeevanandam, Valluvan and Salerno, Christopher and Grinstein, Jonathan},
  title = {Mitigating Post-operative Right Ventricular Dysfunction After Left Ventricular Assist Device: The RV Protection Study},
  journal = {Journal of Cardiac Failure},
  year = {2026},
  doi = {10.1016/j.cardfail.2025.01.017}
}
Kostenlos starten →